Skip to main
PTHS

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics Inc. demonstrates a robust upward trajectory in its prescription volume, evidenced by a 41% sequential increase in written prescriptions from September to October in 4Q25, surpassing the entire third-quarter volume within the initial weeks of the fourth quarter. The expansion of the sales force from 50 to 64 territory managers aims to enhance clinician coverage from approximately 8,000 to 10,000, thereby positioning the company for potential share gains in the expansive impetigo market. As treatment rates are expected to rise alongside improved prescriber adoption and positive feedback from key opinion leaders, Pelthos's existing commercial model is poised for significant revenue contributions from its current and future product offerings.

Bears say

Pelthos Therapeutics Inc. faces significant challenges that could adversely affect its financial performance and stock outlook. The company risks lower-than-expected sales and margins if it fails to secure adequate reimbursement or formulary placement, and slow adoption by healthcare professionals could further hinder revenue growth. Additionally, the potential failure of clinical-stage products to deliver significant trial results or gain regulatory approval poses a substantial threat to the overall value of Pelthos's product candidates, while competitive pressures in the market may limit their ability to capture projected revenues.

PTHS has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Buy based on their latest research and market trends.

According to 6 analysts, PTHS has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.